{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:10:01Z","timestamp":1794006601742,"version":"4.8.0"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1001\/jamaneurol.2018.1487","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T16:20:01Z","timestamp":1529338801000},"page":"1206","source":"Crossref","is-referenced-by-count":305,"title":["Safety and Tolerability of Multiple Ascending Doses of PRX002\/RG7935, an Anti\u2013\u03b1-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease"],"prefix":"10.1001","volume":"75","author":[{"given":"Joseph","family":"Jankovic","sequence":"first","affiliation":[{"name":"Parkinson\u2019s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Goodman","sequence":"additional","affiliation":[{"name":"BioClinica, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Safirstein","sequence":"additional","affiliation":[{"name":"MD Clinical, Hallandale Beach, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya K.","family":"Marmon","sequence":"additional","affiliation":[{"name":"Prothena Biosciences Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale B.","family":"Schenk","sequence":"additional","affiliation":[{"name":"Prothena Biosciences Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Koller","sequence":"additional","affiliation":[{"name":"Prothena Biosciences Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagner","family":"Zago","sequence":"additional","affiliation":[{"name":"Prothena Biosciences Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K.","family":"Ness","sequence":"additional","affiliation":[{"name":"Prothena Biosciences Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue G.","family":"Griffith","sequence":"additional","affiliation":[{"name":"ClinPharma Resources, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grundman","sequence":"additional","affiliation":[{"name":"University of California, San Diego"},{"name":"Global R&D Partners, LLC, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Soto","sequence":"additional","affiliation":[{"name":"Prothena Biosciences Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Ostrowitzki","sequence":"additional","affiliation":[{"name":"Genentech Inc, Product Development, Neuroscience, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Boess","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meret","family":"Martin-Facklam","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Quinn","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland"},{"name":"Portland Veterans Affairs Medical Center, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Isaacson","sequence":"additional","affiliation":[{"name":"Parkinson\u2019s Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Omidvar","sequence":"additional","affiliation":[{"name":"Collaborative Neuroscience Network LLC, Long Beach, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Ellenbogen","sequence":"additional","affiliation":[{"name":"QUEST Research Institute, Farmington Hills, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene G.","family":"Kinney","sequence":"additional","affiliation":[{"name":"Prothena Biosciences Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"noi180037r1","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease.","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"noi180037r2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1055\/s-0037-1601888","article-title":"Diagnosis and management of Parkinson\u2019s disease.","volume":"37","author":"Tarakad","year":"2017","journal-title":"Semin Neurol"},{"key":"noi180037r3","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.12688\/f1000research","article-title":"Progress toward an integrated understanding of Parkinson\u2019s disease.","volume":"6","author":"Rousseaux","year":"2017","journal-title":"F1000Res"},{"issue":"5","key":"noi180037r4","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease.","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat Med"},{"issue":"5","key":"noi180037r5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation.","volume":"14","author":"Li","year":"2008","journal-title":"Nat Med"},{"issue":"2","key":"noi180037r6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease.","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"},{"issue":"6","key":"noi180037r7","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/mds.v31.6","article-title":"Oligomeropathies and pathogenesis of Alzheimer and Parkinson\u2019s diseases.","volume":"31","author":"Forloni","year":"2016","journal-title":"Mov Disord"},{"issue":"5456","key":"noi180037r8","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"issue":"4","key":"noi180037r9","doi-asserted-by":"publisher","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS One"},{"issue":"39","key":"noi180037r10","doi-asserted-by":"publisher","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular a-synuclein prevents cell-to-cell aggregate transmission.","volume":"32","author":"Bae","year":"2012","journal-title":"J Neurosci"},{"issue":"1","key":"noi180037r11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-016-0410-8","article-title":"Anti-a-synuclein immunotherapy reduces a-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.","volume":"5","author":"Spencer","year":"2017","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"noi180037r12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of alpha-synuclein immunization in a mouse model of Parkinson\u2019s disease.","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"issue":"8","key":"noi180037r13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/acn3.321","article-title":"a-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease.","volume":"3","author":"Spencer","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"noi180037r14","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.celrep.2014.05.033","article-title":"?-synuclein immunotherapy blocks uptake and templated propagation of misfolded a-synuclein and neurodegeneration.","volume":"7","author":"Tran","year":"2014","journal-title":"Cell Rep"},{"issue":"28","key":"noi180037r15","doi-asserted-by":"publisher","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson\u2019s disease-like models.","volume":"34","author":"Games","year":"2014","journal-title":"J Neurosci"},{"issue":"3","key":"noi180037r16","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ajpath.2012.11.018","article-title":"Axonopathy in an a-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated a-synuclein.","volume":"182","author":"Games","year":"2013","journal-title":"Am J Pathol"},{"key":"noi180037r17","doi-asserted-by":"publisher","first-page":"S560","DOI":"10.1002\/mds.27072","article-title":"Results from a phase 1b multiple ascending-dose study of PRX002, an anti\u2013alpha-synuclein monoclonal antibody, in patients with Parkinson\u2019s disease.","volume":"32","author":"Jankovic","year":"2017","journal-title":"Mov Disord"},{"issue":"2","key":"noi180037r18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/mds.v32.2","article-title":"First-in-human assessment of PRX002, an anti-a-synuclein monoclonal antibody, in healthy volunteers.","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov Disord"},{"issue":"7","key":"noi180037r19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1517\/14656566.2016.1149163","article-title":"New and emerging medical therapies in Parkinson\u2019s disease.","volume":"17","author":"Lotia","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"noi180037r20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.pharmthera.2014.05.010","article-title":"Emerging therapies for Parkinson\u2019s disease: from bench to bedside.","volume":"144","author":"Tarazi","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"2","key":"noi180037r21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2217\/imt-2017-0146","article-title":"Immunologic treatment of Parkinson\u2019s disease.","volume":"10","author":"Jankovic","year":"2018","journal-title":"Immunotherapy"},{"issue":"4","key":"noi180037r22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3233\/JPD-150642","article-title":"The synaptic function of alpha-synuclein.","volume":"5","author":"Burr\u00e9","year":"2015","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"noi180037r23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.bbadis.2011.10.002","article-title":"?-synuclein misfolding and Parkinson\u2019s disease.","volume":"1822","author":"Breydo","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"6645","key":"noi180037r24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies.","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"issue":"2","key":"noi180037r25","doi-asserted-by":"publisher","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","article-title":"a-Synuclein in Parkinson\u2019s disease.","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"noi180037r26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","article-title":"100 years of Lewy pathology.","volume":"9","author":"Goedert","year":"2013","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"noi180037r27","first-page":"2","article-title":"The search for a peripheral biopsy indicator of alpha-synuclein pathology for Parkinson disease.","volume":"76","author":"Lee","year":"2017","journal-title":"J Neuropathol Exp Neurol"},{"key":"noi180037r28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40478-016-0305-8","article-title":"Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies.","volume":"4","author":"Corbill\u00e9","year":"2016","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"noi180037r29","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ana.24648","article-title":"Pathological a-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients.","volume":"79","author":"Stokholm","year":"2016","journal-title":"Ann Neurol"},{"issue":"5","key":"noi180037r30","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1084\/jem.20112457","article-title":"Intracerebral inoculation of pathological a-synuclein initiates a rapidly progressive neurodegenerative a-synucleinopathy in mice.","volume":"209","author":"Luk","year":"2012","journal-title":"J Exp Med"},{"key":"noi180037r31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40478-014-0088-8","article-title":"Pathological alpha-synuclein propagates through neural networks.","volume":"2","author":"Masuda-Suzukake","year":"2014","journal-title":"Acta Neuropathol Commun"},{"issue":"7556","key":"noi180037r32","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature14547","article-title":"a-Synuclein strains cause distinct synucleinopathies after local and systemic administration.","volume":"522","author":"Peelaerts","year":"2015","journal-title":"Nature"},{"issue":"29","key":"noi180037r33","doi-asserted-by":"publisher","first-page":"10732","DOI":"10.1073\/pnas.1321785111","article-title":"Intramuscular injection of a-synuclein induces CNS a-synuclein pathology and a rapid-onset motor phenotype in transgenic mice.","volume":"111","author":"Sacino","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"noi180037r34","first-page":"1158","article-title":"Transmission of soluble and insoluble alpha-synuclein to mice.","volume":"74","author":"Jones","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"issue":"9","key":"noi180037r35","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1084\/jem.20160368","article-title":"Widespread transneuronal propagation of a-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson\u2019s disease.","volume":"213","author":"Rey","year":"2016","journal-title":"J Exp Med"},{"issue":"6","key":"noi180037r36","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/mds.v31.6","article-title":"Targeting a-synuclein: Therapeutic options.","volume":"31","author":"Dehay","year":"2016","journal-title":"Mov Disord"},{"issue":"1","key":"noi180037r37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s13311-015-0397-z","article-title":"Immunotherapeutic approaches targeting amyloid-beta, alpha-synuclein, and tau for the treatment of neurodegenerative disorders.","volume":"13","author":"Valera","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"2","key":"noi180037r38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/mds.v31.2","article-title":"Development of passive immunotherapies for synucleinopathies.","volume":"31","author":"Bergstr\u00f6m","year":"2016","journal-title":"Mov Disord"},{"issue":"1-3","key":"noi180037r39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12026-007-0003-5","article-title":"Safety of IGIV therapy and infusion-related adverse events.","volume":"38","author":"Ballow","year":"2007","journal-title":"Immunol Res"},{"issue":"6","key":"noi180037r40","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","article-title":"Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.","volume":"13","author":"Chung","year":"2008","journal-title":"Oncologist"},{"issue":"1","key":"noi180037r42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401: a clinical study in Alzheimer\u2019s disease with a protofibril selective A\u00df antibody.","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"noi180037r41","author":"Brys","year":"2017"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/edhub.ama-assn.org\/journals\/jamaneurology\/fullarticle\/2685097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T12:35:47Z","timestamp":1539002147000},"score":1,"resource":{"primary":{"URL":"http:\/\/archneur.jamanetwork.com\/article.aspx?doi=10.1001\/jamaneurol.2018.1487"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2018.1487","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733466919.793576737","asserted-by":"object"}]},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}